Cancer Research and Treatment

Original Article

Sarcoma

Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study: Joonha Kwon, Jun Hyeong Lee, Young Han Lee, Jeeyun Lee, Jin-Hee Ahn, Se Hyun Kim, Seung Hyun Kim, Tae Il Kim, Kum-Hee Yun, Young Suk Park, Jeong Eun Kim, Kyu Sang Lee, Jung Kyoon Choi, Hyo Song Kim; Cancer Res Treat. 2022;54(4):1240-1255. Published online January 17, 2022; DOI: https://doi.org/10.4143/crt.2021.1194

Abstract PDF Supplementary Material PubReader ePub

Purpose
Desmoid tumor, also known as aggressive fibromatosis, is well-characterized by abnormal Wnt/β-catenin signaling. Various therapeutic options, including imatinib, are available to treat desmoid tumor. However, the molecular mechanism of why imatinib works remains unclear. Here, we describe potential roles of NOTCH2 and HES1 in clinical response to imatinib at genome and transcriptome levels.
Materials and Methods
We identified somatic mutations in coding and noncoding regions via whole-genome sequencing. To validate the genetic interaction with expression level in desmoid-tumor condition, we utilized large-scale whole-genome sequencing and transcriptome datasets from the Pan-Cancer Analysis of Whole Genomes project. RNA-sequencing was performed using prospective and retrospective cohort samples to evaluate the expressional relevance with clinical response.
Results
Among 20 patients, four (20%) had a partial response and 14 (66.7%) had stable disease, 11 of which continued for ≥ 1 year. With gene-wise functional analyses, we detected a significant correlation between recurrent NOTCH2 noncoding mutations and clinical response to imatinib. Based on Pan-Cancer Analysis of Whole Genomes data analyses, NOTCH2 mutations affect expression levels particularly in the presence of CTNNB1 missense mutations. By analyzing RNA-sequencing with additional desmoid tumor samples, we found that NOTCH2 expression was significantly correlated with HES1 expression. Interestingly, NOTCH2 had no statistical power to discriminate between responders and non-responders. Instead, HES1 was differentially expressed with statistical significance between responders and non-responders.
Conclusion
Imatinib was effective and well tolerated for advanced desmoid tumor treatment. Our results show that HES1, regulated by NOTCH2, as an indicator of sensitivity to imatinib, and an important therapeutic consideration for desmoid tumor.

Citations

Citations to this article as recorded by

Therapeutical potential of natural products in treatment of pancreatic cancer: a review
Sanjeev Kumar Sahu, Pranav Kumar Prabhakar, Manish Vyas
Molecular Biology Reports.2025;[Epub] CrossRef
Advancing Precision Medicine: The Role of Genetic Testing and Sequencing Technologies in Identifying Biological Markers for Rare Cancers
Joviana Farhat, Lara Alzyoud, Mohammad AlWahsh, Animesh Acharjee, Basem Al‐Omari
Cancer Medicine.2025;[Epub] CrossRef
Clinical and morphological features of desmoid-type fibromatosis
N. B. Pilkevich, R. R. Khabibullin, V. A. Markovskaya, O. V. Yavorskaya, A. P. Smirnova
Yakut Medical Journal.2025; (4): 118. CrossRef
The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects
Chuanxi Zheng, Jianghong Huang, Gang Xu, Wei Li, Xin Weng, Shiquan Zhang
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(1): 166907. CrossRef
Long‐term result of 125I seed brachytherapy for pediatric desmoid tumor in the head and neck
Yi‐Wei Zhong, Xiao‐Ming Lyu, Yan Shi, Chuan‐Bin Guo, Jian‐Guo Zhang, Lei Zheng
Pediatric Blood & Cancer.2023;[Epub] CrossRef
Update on Familial Adenomatous Polyposis-Associated Desmoid Tumors
Wanjun Yang, Pei-Rong Ding
Clinics in Colon and Rectal Surgery.2023; 36(06): 400. CrossRef
Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams
Igino Simonetti, Federico Bruno, Roberta Fusco, Carmen Cutolo, Sergio Venanzio Setola, Renato Patrone, Carlo Masciocchi, Pierpaolo Palumbo, Francesco Arrigoni, Carmine Picone, Andrea Belli, Roberta Grassi, Francesca Grassi, Antonio Barile, Francesco Izzo,
Journal of Personalized Medicine.2022; 12(7): 1153. CrossRef

9,834 View
286 Download
7 Web of Science
7 Crossref

First
Prev
Page of 1
Next
Last

Search